SLC5A2 and prostate cancer: In MVMR analysis, SGLT2 inhibitor and uridine were still associated with prostate cancer [ORSGLT2 inhibitor = 0.43 (95% CI 0.24, 0.77), PSGLT2 inhibitor = 0.005, ORuridine = 1.13 (95% CI 1.08, 1.18), Puridine < 0.001].